Implementation of a radial long sheath protocol for radial artery spasm reduces access site conversions in neurointerventions.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 29 06 2020
revised: 30 07 2020
accepted: 05 08 2020
pubmed: 28 8 2020
medline: 29 6 2021
entrez: 27 8 2020
Statut: ppublish

Résumé

Many neurointerventionalists have transitioned to transradial access (TRA) as the preferred approach for neurointerventions as studies continue to demonstrate fewer access site complications than transfemoral access. However, radial artery spasm (RAS) remains one of the most commonly cited reasons for access site conversions. We discuss the benefits, techniques, and indications for using the long radial sheath in RAS and present our experience after implementing a protocol for routine use. A retrospective review of all patients undergoing neurointerventions via TRA at our institution from July 2018 to April 2020 was performed. In November 2019, we implemented a long radial sheath protocol to address RAS. Patient demographics, RAS rates, radial artery diameter, and access site conversions were compared before and after the introduction of the protocol. 747 diagnostic cerebral angiograms and neurointerventional procedures in which TRA was attempted as the primary access site were identified; 247 were performed after the introduction of the long radial sheath protocol. No significant differences in age, gender, procedure type, sheath sizes, and radial artery diameter were seen between the two cohorts. Radial anomalies and small radial diameters were more frequently seen in patients with RAS. Patients with clinically significant RAS more often required access site conversion (p<0.0001), and in our multivariable model use of the long sheath was the only covariate protective against radial failure (OR 0.061, 95% CI 0.007 to 0.517; p=0.0103). In our experience, we have found that the use of long radial sheaths significantly reduces the need for access site conversions in patients with RAS during cerebral angiography and neurointerventions.

Sections du résumé

BACKGROUND BACKGROUND
Many neurointerventionalists have transitioned to transradial access (TRA) as the preferred approach for neurointerventions as studies continue to demonstrate fewer access site complications than transfemoral access. However, radial artery spasm (RAS) remains one of the most commonly cited reasons for access site conversions. We discuss the benefits, techniques, and indications for using the long radial sheath in RAS and present our experience after implementing a protocol for routine use.
METHODS METHODS
A retrospective review of all patients undergoing neurointerventions via TRA at our institution from July 2018 to April 2020 was performed. In November 2019, we implemented a long radial sheath protocol to address RAS. Patient demographics, RAS rates, radial artery diameter, and access site conversions were compared before and after the introduction of the protocol.
RESULTS RESULTS
747 diagnostic cerebral angiograms and neurointerventional procedures in which TRA was attempted as the primary access site were identified; 247 were performed after the introduction of the long radial sheath protocol. No significant differences in age, gender, procedure type, sheath sizes, and radial artery diameter were seen between the two cohorts. Radial anomalies and small radial diameters were more frequently seen in patients with RAS. Patients with clinically significant RAS more often required access site conversion (p<0.0001), and in our multivariable model use of the long sheath was the only covariate protective against radial failure (OR 0.061, 95% CI 0.007 to 0.517; p=0.0103).
CONCLUSION CONCLUSIONS
In our experience, we have found that the use of long radial sheaths significantly reduces the need for access site conversions in patients with RAS during cerebral angiography and neurointerventions.

Identifiants

pubmed: 32843358
pii: neurintsurg-2020-016564
doi: 10.1136/neurintsurg-2020-016564
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

547-551

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Evan Luther (E)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA evan.luther@jhsmiami.org.

Stephanie H Chen (SH)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

David J McCarthy (DJ)

Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Ahmed Nada (A)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Rainya Heath (R)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Katherine Berry (K)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Allison Strickland (A)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Joshua Burks (J)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Michael Silva (M)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Samir Sur (S)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Dileep R Yavagal (DR)

Neurology and Neurosurgery, University of Miami, Miami, Florida, USA.

Robert M Starke (RM)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Eric C Peterson (EC)

Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH